---
date: "2016-04-27T00:00:00Z"
external_link: ""
image:
  caption: Photo by rawpixel on Unsplash
  focal_point: Smart
links:
- icon: twitter
  icon_pack: fab
  name: Follow
  url: https://twitter.com/georgecushen
slides: example
summary: An example of using the in-built project page.
tags:
- Deep Learning
title: Internal Project
url_code: ""
url_pdf: ""
url_slides: ""
url_video: ""
---

Background: The antitumor efficacy of PARP inhibitors (PARPi) for breast cancer patients harboring germline BRCA1/2
(gBRCA1/2) mutations is well established. While PARPi monotherapy was ineffective in patients with metastatic triple
negative breast cancer (TNBC) wild type for BRCA1/2, we hypothesized that PARPi may be effective in primary TNBCs
without previous chemotherapy exposure.
Patients and methods: In the phase II PETREMAC trial, patients with primary TNBC >2 cm received olaparib for up to
10 weeks before chemotherapy. Tumor biopsies collected before and after olaparib underwent targeted DNA
sequencing (360 genes) and BRCA1 methylation analyses. In addition, BRCAness (multiplex ligation-dependent probe
amplification), PAM50 gene expression, RAD51 foci, tumor-infiltrating lymphocytes (TILs) and PD-L1 analyses were
performed on pretreatment samples.
Results: The median pretreatment tumor diameter was 60 mm (range 25-112 mm). Eighteen out of 32 patients
obtained an objective response (OR) to olaparib (56.3%). Somatic or germline mutations affecting homologous
recombination (HR) were observed in 10/18 responders [OR 55.6%, 95% confidence interval (CI) 33.7-75.4]
contrasting 1/14 non-responders (OR 7.1%; CI 1.3-31.5, P ¼ 0.008). Among tumors without HR mutations, 6/8
responders versus 3/13 non-responders revealed BRCA1 hypermethylation (P ¼ 0.03). Thus, 16/18 responders
(88.9%, CI 67.2-96.9), in contrast to 4/14 non-responders (28.6%, CI 11.7-54.7, P ¼ 0.0008), carried HR mutations
and/or BRCA1 methylation. Excluding one gPALB2 and four gBRCA1/2 mutation carriers, 12/14 responders (85.7%,
CI 60.1-96.0) versus 3/13 non-responders (23.1%, CI 8.2-50.3, P ¼ 0.002) carried somatic HR mutations and/or
BRCA1 methylation. In contrast to BRCAness signature or basal-like subtype, low RAD51 scores, high TIL or high PDL1
expression all correlated to olaparib response.
Conclusion: Olaparib yielded a high clinical response rate in treatment-naïve TNBCs revealing HR deficiency, beyond
germline HR mutations

Cras aliquam rhoncus ipsum, in hendrerit nunc mattis vitae. Duis vitae efficitur metus, ac tempus leo. Cras nec fringilla lacus. Quisque sit amet risus at ipsum pharetra commodo. Sed aliquam mauris at consequat eleifend. Praesent porta, augue sed viverra bibendum, neque ante euismod ante, in vehicula justo lorem ac eros. Suspendisse augue libero, venenatis eget tincidunt ut, malesuada at lorem. Donec vitae bibendum arcu. Aenean maximus nulla non pretium iaculis. Quisque imperdiet, nulla in pulvinar aliquet, velit quam ultrices quam, sit amet fringilla leo sem vel nunc. Mauris in lacinia lacus.

Suspendisse a tincidunt lacus. Curabitur at urna sagittis, dictum ante sit amet, euismod magna. Sed rutrum massa id tortor commodo, vitae elementum turpis tempus. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Aenean purus turpis, venenatis a ullamcorper nec, tincidunt et massa. Integer posuere quam rutrum arcu vehicula imperdiet. Mauris ullamcorper quam vitae purus congue, quis euismod magna eleifend. Vestibulum semper vel augue eget tincidunt. Fusce eget justo sodales, dapibus odio eu, ultrices lorem. Duis condimentum lorem id eros commodo, in facilisis mauris scelerisque. Morbi sed auctor leo. Nullam volutpat a lacus quis pharetra. Nulla congue rutrum magna a ornare.

Aliquam in turpis accumsan, malesuada nibh ut, hendrerit justo. Cum sociis natoque penatibus et magnis dis parturient montes, nascetur ridiculus mus. Quisque sed erat nec justo posuere suscipit. Donec ut efficitur arcu, in malesuada neque. Nunc dignissim nisl massa, id vulputate nunc pretium nec. Quisque eget urna in risus suscipit ultricies. Pellentesque odio odio, tincidunt in eleifend sed, posuere a diam. Nam gravida nisl convallis semper elementum. Morbi vitae felis faucibus, vulputate orci placerat, aliquet nisi. Aliquam erat volutpat. Maecenas sagittis pulvinar purus, sed porta quam laoreet at.
